Exacerbation of pertussis airway inflammation and pathology by pertussis toxin
百日咳毒素加剧百日咳气道炎症和病理学
基本信息
- 批准号:8577405
- 负责人:
- 金额:$ 30.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-05-15 至 2018-04-30
- 项目状态:已结题
- 来源:
- 关键词:ADP ribosylationAcuteAffectAnionsAsthmaBacterial InfectionsBordetella pertussisBradykininBradykinin B2 ReceptorCase StudyCellsCessation of lifeChronic Obstructive Airway DiseaseCollaborationsCommunicable DiseasesCoughingCountryDataDiseaseEpidemicEpithelialG Protein-Coupled Receptor SignalingGenesHumanImmune responseIn VitroIndividualInfantInfectionInflammationInflammation MediatorsInflammatory ResponseKnockout MiceLung diseasesMammalian CellMechanical VentilatorsMediatingMucous body substanceMusNatureNeuronsPathogenesisPathologyPeptidesPertussisPertussis ToxinPertussis VaccineProteinsReagentRespiratory SystemRespiratory Tract InfectionsRespiratory tract structureRiskRoleSignal PathwaySymptomsTestingTherapeutic InterventionTimeToxinUniversitiesUp-RegulationVaccinationVaccinesVirulenceVirulence FactorsViscosityairway epitheliumairway inflammationairway surface liquiddesensitizationdesigneffective therapyexperiencein vivo Modelinfant deathmouse modelneurophysiologynew therapeutic targetnovelpathogenpreventpublic health relevancerespiratoryrespiratory reflexresponsetissue/cell culturetransmission process
项目摘要
DESCRIPTION (provided by applicant): Pertussis (whooping cough) is a respiratory disease of humans caused by acute infection with the bacterial pathogen Bordetella pertussis. In the U.S., despite widespread vaccine use, the number of reported cases in 2012 was at a 60-year high, and many other cases go unreported. Several states experienced their worst pertussis epidemic in over 50 years, with multiple infant deaths and thousands of cases. Individuals suffering from pertussis typically experience debilitating cough episodes that last for weeks, but there is no effective treatment for this disease. B. pertussis infects the respiratory tract and produces a number of toxins that adversely affect the host and modulate host responses. One of these toxins, pertussis toxin (PT), is an important virulence factor uniquely produced by B. pertussis. PT ADP-ribosylates heterotrimeric Gi proteins in mammalian cells, disrupting G protein-coupled receptor (GPCR) signaling pathways and causing a wide range of downstream effects on the cell. We hypothesized that PT contributes to pertussis infection and disease through multiple effects on the host. We previously found that PT has several inhibitory effects on the host immune response, including inhibition of innate immune responses that favor bacterial infection. However, our preliminary data here demonstrate that PT stimulates multiple airway inflammatory responses at the peak of B. pertussis infection, including increased expression of an epithelial anion transporter known as pendrin. Pendrin regulates airway surface liquid volume and mucus viscosity, and is implicated in airway pathology in mouse models of asthma and COPD, and therefore represents a potential contributor to pertussis respiratory pathology. We also have preliminary data that PT increases respiratory levels of the inflammatory mediator bradykinin, a peptide implicated in several airway pathologies including cough, and that PT exacerbates respiratory responses to bradykinin. Therefore, we hypothesize that PT is involved in pertussis airway pathology through multiple effects, including upregulation of factors that contribute to airway pathology (such as pendrin) and exacerbation of respiratory responses to inflammatory mediators (such as bradykinin). Using mouse models of B. pertussis infection combined with complementary in vitro approaches, we will test these hypotheses in two specific aims to determine the roles of these PT-mediated effects in pertussis airway pathology. The broad objective of this project is to understand the role(s) of PT in the respirator pathology of pertussis disease, with a view to identification of possible targets for novel therapeutics to treat and prevent pertussis.
描述(由申请方提供):百日咳(百日咳)是由细菌病原体百日咳博德特氏菌急性感染引起的人类呼吸道疾病。在美国,尽管广泛使用疫苗,但2012年报告的病例数达到60年来的最高水平,许多其他病例没有报告。几个州经历了50多年来最严重的百日咳疫情,多名婴儿死亡,数千例病例。患有百日咳的个体通常会经历持续数周的虚弱咳嗽发作,但这种疾病没有有效的治疗方法。B。百日咳感染呼吸道并产生许多毒素,这些毒素对宿主产生不利影响并调节宿主反应。百日咳毒素(pertussis toxin,PT)是由B产生的一种重要毒力因子。百日咳。PT ADP-核糖基化哺乳动物细胞中的异源三聚体Gi蛋白,破坏G蛋白偶联受体(GPCR)信号传导途径并对细胞产生广泛的下游效应。我们假设PT通过对宿主的多重作用而导致百日咳感染和疾病。我们先前发现PT对宿主免疫应答具有几种抑制作用,包括抑制有利于细菌感染的先天免疫应答。然而,我们的初步数据表明,PT在B峰刺激多种气道炎症反应。百日咳感染,包括上皮阴离子转运蛋白pendrin的表达增加。Pendrin调节气道表面液体体积和粘液粘度,并涉及哮喘和COPD小鼠模型的气道病理学,因此代表百日咳呼吸病理学的潜在贡献者。我们也有初步的数据,PT增加呼吸水平的炎症介质缓激肽,一种肽牵连在几个气道病理,包括咳嗽,PT加剧呼吸反应缓激肽。因此,我们假设PT通过多种效应参与百日咳气道病理学,包括导致气道病理学的因子(如pendrin)上调和对炎症介质(如缓激肽)的呼吸反应加剧。采用小鼠B.百日咳感染结合互补的体外方法,我们将在两个特定的目标,以确定这些PT介导的作用在百日咳气道病理学中的作用来测试这些假设。该项目的主要目的是了解PT在百日咳呼吸道病理学中的作用,以期确定治疗和预防百日咳的新型疗法的可能靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NICHOLAS H CARBONETTI其他文献
NICHOLAS H CARBONETTI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NICHOLAS H CARBONETTI', 18)}}的其他基金
Systems-Level Research in Microbial Pathogenesis
微生物发病机制的系统级研究
- 批准号:
10671611 - 财政年份:2022
- 资助金额:
$ 30.66万 - 项目类别:
Age-dependent role of interferon lambda in protection against pertussis lethality in infants
干扰素 lambda 在防止婴儿百日咳致死方面的年龄依赖性作用
- 批准号:
10591086 - 财政年份:2022
- 资助金额:
$ 30.66万 - 项目类别:
IDO promotes severe manifestations of B. pertussis infection in infants
IDO 促进婴儿百日咳博德特氏菌感染的严重表现
- 批准号:
10286308 - 财政年份:2021
- 资助金额:
$ 30.66万 - 项目类别:
NK cell and interferon gamma deficiency in infant susceptibility to pertussis
NK细胞和γ干扰素缺乏导致婴儿对百日咳的易感性
- 批准号:
10369616 - 财政年份:2021
- 资助金额:
$ 30.66万 - 项目类别:
Age-dependent role of type I interferon in Bordetella pertussis pathogenesis
I 型干扰素在百日咳博德特氏菌发病机制中的年龄依赖性作用
- 批准号:
10078317 - 财政年份:2018
- 资助金额:
$ 30.66万 - 项目类别:
Age-dependent role of type I interferon in Bordetella pertussis pathogenesis
I 型干扰素在百日咳博德特氏菌发病机制中的年龄依赖性作用
- 批准号:
10241992 - 财政年份:2018
- 资助金额:
$ 30.66万 - 项目类别:
Age-dependent role of type I interferon in Bordetella pertussis pathogenesis
I 型干扰素在百日咳博德特氏菌发病机制中的年龄依赖性作用
- 批准号:
10475402 - 财政年份:2018
- 资助金额:
$ 30.66万 - 项目类别:
Age-dependent role of type I interferon in Bordetella pertussis pathogenesis
I 型干扰素在百日咳博德特氏菌发病机制中的年龄依赖性作用
- 批准号:
9788241 - 财政年份:2018
- 资助金额:
$ 30.66万 - 项目类别:
Age-dependent role of type I interferon in Bordetella pertussis pathogenesis
I 型干扰素在百日咳博德特氏菌发病机制中的年龄依赖性作用
- 批准号:
10685140 - 财政年份:2018
- 资助金额:
$ 30.66万 - 项目类别:
Age-dependent role of type I interferon in Bordetella pertussis pathogenesis
I 型干扰素在百日咳博德特氏菌发病机制中的年龄依赖性作用
- 批准号:
10462744 - 财政年份:2018
- 资助金额:
$ 30.66万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 30.66万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 30.66万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 30.66万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 30.66万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 30.66万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 30.66万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 30.66万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 30.66万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 30.66万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 30.66万 - 项目类别:
Operating Grants